Doxorubicin: help and threat in cancer therapy

This article is focused on reviewing the benefit and limitations of utilization of doxorubicin, which is one of the most widely used anticancer drug even though it causes severe side effects. The mechanism of action of common cytostatic drugs is described and special attention is paid to doxorubicin. Its pathway through the body is highlighted and its toxicity is emphasized. Finally, strategy of elimination of the negative effects induced by doxorubicin therapy is mentioned and the most widely approach – the use of liposomes – is summarized.

1. Frank C., Fallah M., Ji J. G., Sundquist J., Hemminki K.: International Journal of Cancer, 134, 1899 (2014).
2. Liu Y. Z., Guo M. Q.: Proteomics, 14, 399 (2014).
3. Urrego D., Tomczak A. P., Zahed F., Stuhmer W., Pardo L. A.: Philosophical Transactions of the Royal Society B-Biological Sciences, 369, (2014).
4. Aarts M., Linardopoulos S., Turner N. C.: Current Opinion in Pharmacology, 13, 529 (2013).
5. Takahashi T.: Yakugaku Zasshi-Journal of the Pharmaceutical Society of Japan, 131, 355 (2011).
6. Minotti G., Menna P., Salvatorelli E., Cairo G., Gianni L.: Pharmacological Reviews, 56, 185 (2004).
7. Sinha B. K., Mimnaugh E. G.: Free Radical Biology and Medicine, 8, 567 (1990).
8. Hahn W. C., Weinberg R. A.: New England Journal of Medicine, 347, 1593 (2002).
9. Zhang Y., Zhang Y. J., Zhao H. Y., Zhai Q. L., Shen Y. F.: Biochimie, 99C, 215 (2014).
10. Kiyosaki K., Nakada C., Hijiya N., Tsukamoto Y., Matsuura K., Nakatsuka K., Daa T., Yokoyama S., Imaizumi M., Moriyama M.: Investigative Ophthalmology & Visual Science, 51, 7 (2010).
11. Benchimol S.: Cell Death and Differentiation, 8, 1049 (2001).
12. Zhang Z., Li M., Rayburn E. R., Hill D. L., Zhang R. W., Wang H.: American Journal of Pharmacogenomics, 5, 247 (2005).
13. Croce C. M.: New England Journal of Medicine, 358, 502 (2008).
14. Liu H.-K., Sadler P. J.: Accounts of Chemical Research, 44, 349 (2011).
15. Xu X. X., Persson H. L., Richardson D. R.: Molecular Pharmacology, 68, 261 (2005).
16. Zheng Z., Pavlidis P., Chua S., D'Agati V. D., Gharavi A. G.: Journal of the American Society of Nephrology, 17, 1796 (2006).
17. Wang Y., Wang Y. P., Tay Y. C., Harris D. C. H.: Kidney International, 58, 1797 (2000).
18. Rook M., Lely A. T., Kramer A. B., van Goor H., Navis G.: Nephrology Dialysis Transplantation, 20, 59 (2005).
19. Lal S., Mahajan A., Chen W. N., Chowbay B.: Current Drug Metabolism, 11, 115 (2010).
20. Carvalho C., Santos R. X., Cardoso S., Correia S., Oliveira P. J., Santos M. S., Moreira P. I.: Current Medicinal Chemistry, 16, 3267 (2009).
21. Chatterjee K., Zhang J., Honbo N., Karliner J. S.: Cardiology, 115, 155 (2010).
22. Sakata Y., Dong J.-W., Vallejo J. G., Huang C.-H., Baker J. S., Tracey K. J., Tacheuchi O., Akira S., Mann D. L.: American Journal of Physiology-Heart and Circulatory Physiology, 292, H503 (2007).
23. Wang J. X., Yuan Z. X.: Cell Biochemistry and Biophysics, 67, 199 (2013).
24. Anders C. K., Adamo B., Karginova O., Deal A. M., Rawal S., Darr D., Schorzman A., Santos C., Bash R., Kafri T., Carey L., Miller C. R., Perou C. M., Sharpless N., Zamboni W. C.: Plos One, 8, (2013).
25. Gabizon A., Shmeeda H., Barenholz Y.: Clinical Pharmacokinetics, 42, 419 (2003).
26. Nogueira E., Loureiro A., Nogueira P., Freitas J., Almeida C. R., Harmark J., Hebert H., Moreira A., Carmo A. M., Preto A., Gomes A. C., Cavaco-Paulo A.: Faraday Discussions, 166, 417 (2013).
27. Hashizume H., Baluk P., Morikawa S., McLean J. W., Thurston G., Roberge S., Jain R. K., McDonald D. M.: American Journal of Pathology, 156, 1363 (2000).
28. von Mehren M., Schilder R. J., Cheng J. D., Temmer E., Cardoso T. M., Renshaw F. G., Bayever E., Zannikos P., Yuan Z., Cohen R. B.: Annals of Oncology, 19, 1802 (2008).
29. Orditura M., Quaglia F., Morgillo F., Martinelli E., Lieto E., De Rosa G., Comunale D., Diadema M. R., Ciardiello F., Catalano G., De Vita F.: Oncology Reports, 12, 549 (2004).

PDF